LONDON - ReNeuron plc has finally got the go-ahead for a clinical trial of its fetal neural stem cell treatment, securing the approval of UK regulators to treat 12 patients who are disabled following an ischemic stroke. (BioWorld International)

The team behind two recent successful start-ups, U3 Pharma AG and NeurImmune Therapeutics AG, is applying the lessons learned from those ventures to a new investment fund and has already completed its first deal, a CHF10 million (US$8.9 million) Series A round in start-up firm CT Atlantic AG. (BioWorld International)